Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma

Journal of Geriatric Oncology

Volumn 4, Issue 2, 2013, Pages 128-133

  Pal, Sumanta K ^a   Hsu, JoAnn ^a   Hsu, Sarah ^a   Hu, Jensen ^a   Bergerot, Paulo ^b   Carmichael, Courtney ^a   Saikia, Junmi ^a   Liu, Xueli ^a   Lau, Clayton ^a   Twardowski, Przemyslaw ^a   Figlin, Robert A ^c   Yuh, Bertram E ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Health Department of Federal District (SES) HRAN   (Brazil)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Elderly; Older adults; Renal cell carcinoma; Survival; Targeted therapy

Indexed keywords

INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VASCULOTROPIN INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLEAR CELL CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEPHRECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PYRROLES; RISK ASSESSMENT;

EID: 84875597312     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.11.001     Document Type: Article

References (26)

1. Pal S.K., Figlin R.A. Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol Jun. 2010, 5(2):131-138.
2. Motzer R.J., Bacik J., Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res Sep. 15 2004, 10(18 Pt 2):6302S-6303S.
3. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med May 31 2007, 356(22):2271-2281.
4. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol August 1 2009, 27(22):3584-3590.
5. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol Mar. 1995, 13(3):688-696.
6. Plimack E.R., Jonasch E., Bekele B.N., Qiao W., Ng C.S., Tannir N.M. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study. J Clin Oncol (Meet Abstr) May 20 2010, 28(15_suppl):4604.
7. Verma J., Jonasch E., Allen P., Tannir N.M., Mahajan A. Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: a retrospective review. ASCO Meet Abstr 2011, 29(7_suppl):340.
8. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet Aug. 9 2008, 372(9637):449-456.
9. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol February 20 2010, 28(6):1061-1068.
10. Surveillance, epidemiology and end results (SEER) fast facts sheets: kidney and renal pelvis Available on-line at, [last accessed July 15, 2012]. http://seer.cancer.gov/statfacts/html/kidrp.html.
11. Pal S.K., Vanderwalde A., Hurria A., Figlin R.A. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging Aug. 1 2011, 28(8):635-649.
12. Bellmunt J., Negrier S., Escudier B., Awada A., Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol Jan. 2009, 69(1):64-72.
13. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol Dec. 1 2009, 27(34):5794-5799.
14. Khambati H., Choueiri T.K., Kollmannsberger C.K., North S., Bjarnason G.A., Vaishampayan U.N., et al. Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population. Presented at the 2011 Genitourinary Cancers Symposium [Abstr 318] 2011.
15. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1(3):237-246. 10.1016/S1535-6108(02)00043-0.
16. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol December 15 2004, 22(24):4991-5004.
17. Rodriguez A., Patard J.J., Lobel B. Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature. Arch Esp Urol Oct. 2002, 55(8):969-975.
18. Gillett M.D., Cheville J.C., Karnes R.J., Lohse C.M., Kwon E.D., Leibovich B.C., et al. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol Jun. 2005, 173(6):1893-1896.
19. Baker S.D., van Schaik R.H., Rivory L.P., Ten Tije A.J., Dinh K., Graveland W.J., et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res Dec. 15 2004, 10(24):8341-8350.
20. Sotaniemi E.A., Arranto A.J., Pelkonen O., Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther Mar. 1997, 61(3):331-339.
21. Ranpura V., Pulipati B., Chu D., Zhu X., Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens May 2010, 23(5):460-468.
22. Cohen L., Curhan G.C., Forman J.P. Influence of age on the association between lifestyle factors and risk of hypertension. J Am Soc Hypertens Jul. 2012, 6(4):284-290.
23. Escudier B., Bellmunt J., Negrier S., Bajetta E., Melichar B., Bracarda S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol May 1 2010, 28(13):2144-2150.
24. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med January 11 2007, 356(2):125-134.
25. Hurria A., Cirrincione C.T., Muss H.B., Kornblith A.B., Barry W., Artz A.S., et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol Apr. 1 2011, 29(10):1290-1296.
26. Kader A.K., Tamboli P., Luongo T., Matin S.F., Bell K., Jonasch E., et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol Mar. 2007, 177(3):855-860. [discussion 60-1].